Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.

Given the benefit seen in Case 1, the patient in Case 2 received venetoclax KCd-PAVE for upfront induction therapy in the setting of IHC BCL2 positivity. Cytogenic properties of pPCL provide opportunities to explore novel treatment regimens. Given that high BCL2 expression is not limited to the t(11;14) population, all patients should be tested for BCL2 gene and protein expression. As seen in our case, IHC assessment of BCL2 can guide consideration of venetoclax for upfront induction therapy for pPCL with regimens such as KPD-PAVE and KCd-PAVE. [Extracted from the article]